•  
  •  
 

Abstract

Background: Pancreatic dysfunction is widely acknowledged as a critical issue in individuals with breast cancer. These biomarkers like insulin, lipase, and amylase or polymorphisms such as TCF7L2 can be correlated in assessing breast cancer in conjunction with other medicine relations such as pancreatic health. Objective: The aim of this particular study is to assess the role of breast cancer in pancreatic dysfunction by assessing the aforementioned biomarkers and gene polymorphisms. Methods: Following ethical guidelines, a case-control study was conducted involving female patients diagnosed with breast cancer and other breast cancer-free women. Various combined diagnostic tests, including ROC curve analysis and lognormal QQ plots, were performed to measure and analyze normal range serum levels of amylase, insulin, and lipase. These, along with PCR-based genotyping for TCF7L2 gene polymorphisms, were carried out in groups. Results: According to the research undertaken, compared to the controls, significant differences in lipase levels were observed in patients diagnosed with breast cancer due to tumors. ROC analysis indicated that lipase showed an AUC of 0.72, indicating a potential role as a biomarker for pancreatic dysfunction. while amylase levels showed an AUC of 0.63, and insulin levels had a low diagnostic utility. Analysis of the TCF7L2 gene polymorphism revealed that a higher frequency of the GG genotype is present in patients, suggesting that it might be associated with the increased risk of developing pancreatic dysfunction. Conclusion: It has been shown that in breast cancer patients, lipase can be used as a biomarker for detecting pancreatic dysfunction; however, amylase and insulin cannot be recommended.

Article Type

Article

First Page

46

Last Page

54

Creative Commons License

Creative Commons Attribution 4.0 International License
This work is licensed under a Creative Commons Attribution 4.0 International License.

Download

Share

COinS